We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals
JAZZ

323 hedge funds and large institutions have $8.13B invested in Jazz Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 108 increasing their positions, 115 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more funds holding in top 10

Funds holding in top 10: 6 → 11 (+5)

12% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 41

11% more capital invested

Capital invested by funds: $7.32B → $8.13B (+$808M)

0% more funds holding

Funds holding: 323 → 323 (0)

0.66% less ownership

Funds ownership: 90.8% → 90.14% (-0.66%)

6% less call options, than puts

Call options by funds: $31.7M | Put options by funds: $33.7M

6% less repeat investments, than reductions

Existing positions increased: 108 | Existing positions reduced: 115

Holders
323
Holders Change
–
Holders Change %
0%
% of All Funds
7.4%
Holding in Top 10
11
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+83.33%
% of All Funds
0.25%
New
46
Increased
108
Reduced
115
Closed
41
Calls
$31.7M
Puts
$33.7M
Net Calls
-$2.02M
Net Calls Change
+$33.4M

Top Buyers

1
PHS
PFM Health Sciences
California
+$167M
2
O
OrbiMed
New York
+$63.4M
3
TCIM
TIAA CREF Investment Management
New York
+$38.1M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$33.1M
5
Millennium Management
Millennium Management
New York
+$28.4M

Top Sellers

1
PI
Putnam Investments
Massachusetts
-$160M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$142M
3
Renaissance Technologies
Renaissance Technologies
New York
-$42M
4
AAMU
Amundi Asset Management US
Massachusetts
-$31.6M
5
American Century Companies
American Century Companies
Missouri
-$22.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
$58.5M +$33.1M +225,751 +140%
UBS Group
27
UBS Group
Switzerland
$57.3M +$1.5M +10,256 +3%
Adage Capital Partners
28
Adage Capital Partners
Massachusetts
$52.7M -$17.5M -119,186 -25%
Franklin Resources
29
Franklin Resources
California
$52.5M -$4.52M -30,800 -8%
American Century Companies
30
American Century Companies
Missouri
$51.6M -$22.9M -156,157 -31%
APG Asset Management
31
APG Asset Management
Netherlands
$50.9M +$455K +3,100 +0.8%
Dimensional Fund Advisors
32
Dimensional Fund Advisors
Texas
$44.1M +$5.5M +37,486 +15%
BNP Paribas Asset Management
33
BNP Paribas Asset Management
France
$41.3M -$412K -2,811 -1%
Morgan Stanley
34
Morgan Stanley
New York
$41.2M +$4.68M +31,923 +13%
EVM
35
Eaton Vance Management
Massachusetts
$36M +$17.7M +120,362 +102%
Legal & General Group
36
Legal & General Group
United Kingdom
$35.8M -$20.4K -139 -0.1%
Baird Financial Group
37
Baird Financial Group
Wisconsin
$35.3M +$8.37M +57,025 +32%
Invesco
38
Invesco
Georgia
$35M -$4.24M -28,910 -11%
Northern Trust
39
Northern Trust
Illinois
$35M +$1.8M +12,252 +6%
LSV Asset Management
40
LSV Asset Management
Illinois
$34.8M +$10.4M +71,100 +45%
Two Sigma Investments
41
Two Sigma Investments
New York
$34.8M +$13.3M +90,752 +65%
UBS AM
42
UBS AM
Illinois
$34.3M +$5.21M +35,511 +19%
Schroder Investment Management Group
43
Schroder Investment Management Group
United Kingdom
$33.4M -$4.78M -32,600 -13%
Millennium Management
44
Millennium Management
New York
$33.3M +$28.4M +193,347 +708%
SO
45
STRS Ohio
Ohio
$33.1M -$643K -4,380 -2%
Charles Schwab
46
Charles Schwab
California
$33M +$1.67M +11,355 +5%
Bank of America
47
Bank of America
North Carolina
$32.2M +$3.47M +23,679 +12%
BGIM
48
Brandywine Global Investment Management
Pennsylvania
$31.1M -$465K -3,171 -2%
Deutsche Bank
49
Deutsche Bank
Germany
$29.1M -$12.6M -85,711 -31%
Swiss National Bank
50
Swiss National Bank
Switzerland
$29M -$4.27M -29,100 -13%
1
2
3 4 5

JAZZ Hedge Fund Activity: Q1 2018 in Review

323 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2018, worth a combined $8.13B — up 11% from $7.32B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new JAZZ positions and 41 closed out — a net gain of 5 holders — while 108 added to existing stakes and 115 trimmed.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $167M. The largest seller was Putnam Investments, cutting an estimated $160M.

  • 323 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $8.13B of Jazz Pharmaceuticals stock for Q1 2018, up 11% quarter-over-quarter.
  • 46 funds opened new Jazz Pharmaceuticals positions in Q1 2018 and 41 closed out, a net change of +5 holders.
  • The largest Jazz Pharmaceuticals buyer in Q1 2018 was PFM Health Sciences, an estimated $167M added.
  • The largest Jazz Pharmaceuticals seller in Q1 2018 was Putnam Investments, an estimated $160M sold.

Based on aggregated 13F filings for Q1 2018.